Barclays
CTMX icon

Barclays’s CytomX Therapeutics CTMX Stock Holding History

Barclays’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.29M Buy
+700,000
New +$3.55M ﹤0.01% 2068

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Barclays's CTMX Position: Q1 2026 in Review

Barclays reduced its CytomX Therapeutics (CTMX) stake by 58% in Q1 2026, selling an estimated $985K and leaving 142,412 shares worth $669K. The position accounts for ﹤0.01% of the portfolio, ranked #3002.

Barclays first reported a position in CTMX in Q4 2015 and has held it in 29 quarters since. The position peaked at $1.43M in Q4 2025. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Barclays held 142,412 shares of CytomX Therapeutics worth $669K as of Q1 2026.
  • Barclays sold 194,113 CytomX Therapeutics shares in Q1 2026, an estimated $985K.
  • CytomX Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3002 holding.
  • Barclays first reported a position in CytomX Therapeutics in Q4 2015 and has held it in 29 quarters since.
  • Barclays's CytomX Therapeutics position peaked at $1.43M in Q4 2025.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.